Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 11/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.33 |
| ▸ | RXRA | P19793 | 4/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328263 | 0.82 | C5AR1 (0.41) | C5AR1 | |
| SCHEMBL1328513 | 0.80 | C5AR1 (0.37) | C5AR1 | |
| SCHEMBL1326765 | 0.77 | C5AR1 (0.39) | C5AR1 | |
| SCHEMBL1328413 | 0.77 | C5AR1 (0.36) | C5AR1 | |
| SCHEMBL1328686 | 0.77 | C5AR1 (0.47) | C5AR1 | |
| SCHEMBL1327995 | 0.76 | C5AR1 (0.40) | C5AR1L3MBTL1 | |
| SCHEMBL1327388 | 0.73 | C5AR1 (0.42) | C5AR1 | |
| SCHEMBL1328528 | 0.70 | C5AR1 (0.38) | C5AR1 | |
| SCHEMBL1326928 | 0.70 | C5AR1 (0.38) | C5AR1 | |
| SCHEMBL1328179 | 0.69 | C5AR1 (0.40) | C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565452-B1 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NOVARTIS INT PHARM LTD (BM) | 2012-04-04 | — | — | EP | disclosed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1565452-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885PDE5A 519/4885PDE4A 482/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885PDE5A 519/4885PDE4A 482/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885PDE5A 756/4885PDE4A 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.